About this reference
This page provides a factual reference of FDA-approved GLP-1 receptor agonist medications based on publicly available information. It includes brand names, generic names, manufacturers, FDA approval dates, approved indications, and administration methods.
This page does not include dosage information or treatment recommendations. Medication selection, dosing, and treatment plans should be determined by your healthcare provider based on your individual health profile. For a deeper look at the science behind these medications, see our What Are GLP-1 Medications? guide.
Semaglutide medications
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is available under multiple brand names for different approved indications.
Ozempic®
FDA 2017- Generic name
- Semaglutide
- Manufacturer
- Novo Nordisk
- Approved indication
- Type 2 diabetes mellitus — as an adjunct to diet and exercise to improve glycemic control
- Administration
- Once-weekly subcutaneous injection
- Key trial
- SUSTAIN program
Wegovy®
FDA 2021- Generic name
- Semaglutide
- Manufacturer
- Novo Nordisk
- Approved indication
- Chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition
- Administration
- Once-weekly subcutaneous injection
- Key trial
- STEP program
Rybelsus®
FDA 2019- Generic name
- Semaglutide (oral formulation)
- Manufacturer
- Novo Nordisk
- Approved indication
- Type 2 diabetes mellitus — as an adjunct to diet and exercise to improve glycemic control
- Administration
- Daily oral tablet (first oral GLP-1)
- Key trial
- PIONEER program
Tirzepatide medications (dual GIP/GLP-1)
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It targets both the GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, distinguishing it from pure GLP-1 receptor agonists.
Mounjaro®
FDA 2022- Generic name
- Tirzepatide
- Manufacturer
- Eli Lilly
- Approved indication
- Type 2 diabetes mellitus — as an adjunct to diet and exercise to improve glycemic control
- Administration
- Once-weekly subcutaneous injection
- Key trial
- SURPASS program
- Mechanism
- Dual GIP and GLP-1 receptor agonist
Zepbound®
FDA 2023- Generic name
- Tirzepatide
- Manufacturer
- Eli Lilly
- Approved indication
- Chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition
- Administration
- Once-weekly subcutaneous injection
- Key trial
- SURMOUNT program
- Mechanism
- Dual GIP and GLP-1 receptor agonist
Additional GLP-1 medications
Several other GLP-1 receptor agonists are available and continue to be widely prescribed.
Saxenda®
- Generic name
- Liraglutide
- Manufacturer
- Novo Nordisk
- Approved indication
- Chronic weight management
- Administration
- Once-daily subcutaneous injection
Victoza®
- Generic name
- Liraglutide
- Manufacturer
- Novo Nordisk
- Approved indication
- Type 2 diabetes mellitus
- Administration
- Once-daily subcutaneous injection
Trulicity®
- Generic name
- Dulaglutide
- Manufacturer
- Eli Lilly
- Approved indication
- Type 2 diabetes mellitus
- Administration
- Once-weekly subcutaneous injection
Note: Additional GLP-1 receptor agonists exist, including exenatide (Byetta, Bydureon) and lixisenatide (Adlyxin). This page focuses on the most commonly prescribed medications. Approved indications and formulations may change — consult your prescriber for the most current information.
Clinical trial results comparison
Published average weight loss results from pivotal clinical trials. Individual results vary significantly.
| Medication | Trial | Participants | Duration | Avg. weight loss | Placebo |
|---|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy®) | STEP 1 | 1,961 | 68 weeks | ~14.9% | 2.4% |
| Tirzepatide 15mg (Zepbound®) | SURMOUNT-1 | 2,539 | 72 weeks | ~20.9% | 3.1% |
| Liraglutide 3.0mg (Saxenda®) | SCALE | 3,731 | 56 weeks | ~8.0% | 2.6% |
Sources: STEP 1 — Wilding et al., NEJM (2021); SURMOUNT-1 — Jastreboff et al., NEJM (2022); SCALE — Pi-Sunyer et al., NEJM (2015).
Note: Weight loss percentages represent averages from the highest dose groups in each trial. All trials included lifestyle intervention (diet and exercise counseling). Individual results vary significantly. These comparisons are informational and do not constitute medical recommendations.
See detailed weight loss results and timelines
Semaglutide vs. tirzepatide
The two most-discussed GLP-1 medication classes differ in mechanism, available formulations, and clinical trial outcomes.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | Pure GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Formulations | Available as weekly injection and daily oral tablet | Available as weekly injection only (currently) |
| Approvals | Approved for both T2D (Ozempic®) and weight management (Wegovy®) | Approved for both T2D (Mounjaro®) and weight management (Zepbound®) |
| Pivotal trial | STEP 1 trial: ~14.9% average weight loss | SURMOUNT-1 trial: ~20.9% average weight loss (highest dose) |
| Manufacturer | Novo Nordisk | Eli Lilly |
Track any GLP-1 medication with Dose AI
Regardless of which GLP-1 medication you're prescribed, Dose AI provides the same comprehensive tracking experience. Log injections, monitor nutrition, track weight trends, and record symptoms — all in one app designed specifically for GLP-1 users.
Dose AI is a tracking and information tool, not a medical device. Always consult your healthcare provider for medical advice about your GLP-1 medication.
